Phase i dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1499-1506

  Patnaik, Amita ^a   Papadopoulos, Kyriakos P ^a   Tolcher, Anthony W ^a   Beeram, Muralidhar ^a   Urien, Saïk ^b   Schaaf, Larry J ^c   Tahiri, Sanaa ^c   Bekaii Saab, Tanios ^c   Lokiec, François M ^b   Rezaï, Keyvan ^b   Buchbinder, Aby ^d  

^a South Texas Accelerated Research Therapeutics (START)   (United States)

^b INSTITUT CURIE   (France)

^c OHIO STATE UNIVERSITY   (United States)

^d Enzon Incorporated   (United States)

Author keywords

Phase I clinical trials; Polyethylene glycol; SN38; Topoisomerase 1 inhibitors

Indexed keywords

FIRTECAN; FIRTECAN PEGOL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; TOPOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CARCINOID; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; GENE; GENE MUTATION; GENOTYPE; HUMAN; HYPERPIGMENTATION; HYPOKALEMIA; HYPOMAGNESEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; SIDE EFFECT; SOFT TISSUE SARCOMA; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE; UGT1A1 GENE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; POLYETHYLENE GLYCOLS; PRODRUGS; TREATMENT OUTCOME;

EID: 84878651631     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2149-2     Document Type: Article

References (23)

1. Chabot GG (1977) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-259
2. Zhao H, Rubio B, Sapra P et al (2008) Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 19:849-859
3. Sapra P, Zhao H, Mehlig M et al (2008) Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res 14:1888-1896
4. Sapra P, Kraft P, Mehlig M et al (2009) Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma. Haematologica 94:1456-1459
5. Pastorino F, Loi M, Sapra P et al (2010) Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor. Clin Cancer Res 16:4809-4821
6. Sapra P, Kraft P, Pastorino F et al (2011) Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 14:245-253
7. Sparreboom A, de Jonge MJA, de Bruijn P et al (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 4:2747-2754
8. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266
9. Mathijssen RHJ, de Jong FA, van Schaik RHN et al (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592
10. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
11. Omura GA (2003) Modified Fibonacci search. J Clin Oncol 21:3177
12. Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Analysis 49:1020-1038
13. Kuhn E, Lavielle M (2004) Coupling a stochastic approximation version of EM with a MCMC procedure. ESAIM P&S 8:115-131
14. Kurzrock R, Goel S, Wheler J et al (2012) Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer 118:6144-6151
15. Camptosar® (irinotecan hydrochloride injection) package insert, Pfizer, NY. August 2010. http://media.pfizer.com/files/products/uspi-camptosar. pdf
16. Hu ZY, Yu Q, Zhao YS (2010) Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 46:1856-1965
17. de Jong FA, Kehrer DFS, Mathijssen RHJ et al (2006) Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11:944-954
18. Dodds HM, Tobin PJ, Stewart CF et al (2002) The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. J Pharmacol Exp Ther 303:649-655
19. Iyer L, King CD, Whitington PF et al (1998) Genetic predisposition to the metabolism of irinotecan. Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854
20. Sai K, Kaniwa N, Ozawa S, Sawada J (2001) A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4. Drug Metab Dispos 29:1505-1513
21. Takasuna K, Hagiwara T, Hirohashi M et al (1996) Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride in rats. Cancer Res 56:3752-3757
22. Toffoli G, Cecchin E, Gasparini G et al (2010) Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol l28:866-871
23. Dodds HM, Hanrahan J, Rivory LR (2001) The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables. Anticancer Drug Des 16:239-246